EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection

Roshan Ghimire iD, Rakshya Shrestha iD, Radhika Amaradhi, Lin Liu iD, Sunil More, Thota Ganesh iD, Alexandra K Ford iD, Rudragouda Channappanavar iD

Journal of Virology · 2025

DOI: 10.1128/jvi.01668-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Roshan Ghimire und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, COVID-19, SARS-CoV-2, Membrane Glycoproteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced impaired antiviral immunity and excessive inflammatory responses cause lethal pneumonia. However, the in vivo roles of key pattern recognition receptors that elicit protective antiviral and fatal inflammatory responses, specifically in the lungs, are not well described. Coronaviruses possess single-stranded RNA genome that activates TLR7/8 to induce an antiviral interferon (IFN) and robust inflammatory cytokine response. Here, using wild-type and TLR7-deficient (TLR7 −/− ) mice infected with mouse-adapted SARS-CoV-2 (MA-CoV-2), we examined the role of TLR7 in the lung antiviral and inflammatory response and severe pneumonia. We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality, which correlated with reduced levels of type I IFNs ( Ifna/b ), type III IFNs ( Ifnl ), and IFN-stimulated genes (ISGs) in the lungs. A detailed evaluation of MA-CoV-2-infected lungs revealed increased neutrophil accumulation and lung pathology in TLR7 −/− mice. We further showed that blocking type I IFN receptor (IFNAR) signaling enhanced SARS-CoV-2 replication in the lungs and caused severe lung pathology, leading to 100% mortality compared to infected control mice. Moreover, immunohistochemical assessment of the lungs revealed increased numbers of SARS-CoV-2 antigen-positive macrophages, pneumocytes, and bronchial epithelial cells in TLR7 −/− and IFNAR-deficient mice compared to control mice. In summary, we conclusively demonstrated that despite TLR7-induced robust lung inflammation, TLR7-induced IFN/ISG responses suppress lung virus replication and pathology and provide protection against SARS-CoV-2-induced fatal pneumonia. Additionally, given the similar disease outcomes in control, TLR7 −/− , and IFNAR-deficient MA-CoV-2-infected mice and coronavirus disease 2019 (COVID-19) patients, we propose that MA-CoV-2-infected mice constitute an excellent model for studying COVID-19. IMPORTANCE Severe coronavirus disease 2019 (COVID-19) is caused by a delicate balance between a strong antiviral and an exuberant inflammatory response. A robust antiviral immunity and regulated inflammation are protective, while a weak antiviral response and excessive inflammation are detrimental. However, the key host immune sensors that elicit protective antiviral and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge are poorly defined. Here, we examined the role of viral RNA-mediated TLR7 activation in the lung antiviral and inflammatory responses in SARS-CoV-2-infected mice. We demonstrate that TLR7 deficiency led to a high rate of morbidity and mortality, which correlated with an impaired antiviral interferon (IFN)-I/III response, enhanced lung virus replication, and severe lung pathology. Furthermore, we show that blocking IFN-I signaling using anti-IFN receptor antibody promoted SARS-CoV-2 replication in the lungs and caused severe disease. These results provide conclusive evidence that TLR7 and IFN-I receptor deficiencies lead to severe disease in mice, replicating clinical features observed in COVID-19 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7COVID-19SARS-CoV-2Membrane GlycoproteinsAnimalsMiceLungMice, KnockoutMice, Inbred C57BLInterferon Type IDisease Models, AnimalViral LoadVirus ReplicationInterferons

Stichwörter der Autor:innen

SARS-CoV-2TLR7inflammationinterferonmyeloid cells

Substanzen

Toll-Like Receptor 7Tlr7 protein, mouseInterferon Type IMembrane GlycoproteinsInterferons

Autor:innen und Institutionen

  • Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA.
  • Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA.
  • Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, USA.

ORCID-Profile: Roshan Ghimire, Rakshya Shrestha, Lin Liu, Thota Ganesh, Alexandra K Ford, Rudragouda Channappanavar

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Ghimire, R., Shrestha, R., Amaradhi, R., Liu, L., More, S., Ganesh, T., Ford, A. K., & Channappanavar, R. (2025). Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection. Journal of Virology. https://doi.org/10.1128/jvi.01668-24

Vancouver

Ghimire R, Shrestha R, Amaradhi R, Liu L, More S, Ganesh T, et al. Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection. Journal of Virology. 2025. doi:10.1128/jvi.01668-24

BibTeX
@article{Ghimire2025,
  author = {Ghimire, Roshan and Shrestha, Rakshya and Amaradhi, Radhika and Liu, Lin and More, Sunil and Ganesh, Thota and Ford, Alexandra K and Channappanavar, Rudragouda},
  title = {Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01668-24}
}
Kostenlos starten →